ADAP Advocacy Challenges 340B Drug Pricing Program's Current Implementation
TL;DR
ADAP Advocacy supports patients in 340B Program by challenging Health Resources Services Administration, advocating for patient-centric approach to drug pricing.
ADAP Advocacy and CF United file amicus curiae briefs outlining flaws in 340B Program, focusing on patient care and rebate model to ensure fair pricing.
ADAP Advocacy's efforts aim to protect patients in 340B Program, advocating for reforms to prioritize patient well-being and equitable access to healthcare.
ADAP Advocacy highlights patient-focused approach in challenging 340B Program, emphasizing the importance of health equity and real-life impact of program reforms.
Found this article helpful?
Share it with your network and spread the knowledge!
Advocacy organization ADAP Advocacy has filed two amicus curiae briefs supporting a legal challenge against the Health Resources Services Administration regarding the 340B Drug Pricing Program. The briefs, filed jointly with CF United, critically examine the program's expansion and its impact on patient care.
The organization argues that the 340B Program has become increasingly problematic, with hospital systems and service providers potentially exploiting the program for financial gain. Brandon M. Macsata, CEO of ADAP Advocacy, noted that patients are being overlooked, highlighting the estimated $220 billion in medical debt in the United States.
William Sarraille, ADAP Advocacy's Special Counsel for 340B Issues, emphasized the need to refocus the program on patient benefits. He suggested that the rebate model could provide transparency about how drug therapy revenues are generated and distributed.
The advocacy group's primary concerns include disproportionate executive compensation, insufficient charity care, and a program structure that appears to prioritize institutional profits over patient care. Guy Anthony, Chair of the ADAP Advocacy 340B Patient Advisory Committee, stressed the program's importance for people living with HIV while calling for meaningful reform.
These legal briefs represent a significant challenge to the current 340B Drug Pricing Program, potentially signaling a pivotal moment in healthcare policy that could reshape how pharmaceutical pricing and medical support systems operate.
Curated from 24-7 Press Release
